Lantus, Toujeo & Biosimilars
*Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr) are FDA-designated interchangeable biosimilars to Lantus. Basaglar is a follow-on/biosimilar product but is not interchangeable.
Indications
Insulin glargine is a long-acting human insulin analog produced by recombinant DNA technology in Escherichia coli (K12 strain). It differs from human insulin by a single amino acid substitution at position A21 (asparagine → glycine) and the addition of two arginines at the C-terminus of the B-chain. These modifications shift the isoelectric point such that insulin glargine is fully soluble at acidic pH (~4) but precipitates upon injection into the neutral pH of subcutaneous tissue, forming a microprecipitate from which insulin glargine is slowly released. The result is a relatively constant, peakless glucose-lowering profile over 24 hours with U-100 (Lantus, Basaglar, Semglee, Rezvoglar) and an even flatter, more prolonged profile with U-300 (Toujeo).
Lantus (insulin glargine U-100) was the first long-acting basal insulin analog approved in the United States in April 2000 (Sanofi-Aventis), and remains the most widely prescribed basal insulin globally. Toujeo (insulin glargine U-300, approved February 2015) provides three times the concentration in one-third the volume, producing a slower, more prolonged release that may reduce nocturnal hypoglycemia versus U-100 in some populations. The interchangeable biosimilars Semglee (insulin glargine-yfgn, interchangeable status July 2021) and Rezvoglar (insulin glargine-aglr, biosimilar approval December 2021; interchangeable status November 2022) provide lower-cost alternatives clinically equivalent to Lantus.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Diabetes mellitus — Lantus, Basaglar, Semglee, Rezvoglar (U-100) | Adult and pediatric patients with diabetes mellitus (FDA pediatric efficacy data from Study D, ages 6–15 years with T1DM) | Basal insulin component of basal-bolus regimen, basal-only therapy with oral antihyperglycemics in T2DM, or as monotherapy | FDA Approved |
| Diabetes mellitus — Toujeo (U-300) | Adults and pediatric patients aged ≥6 years with diabetes mellitus | Basal insulin; same therapeutic role as U-100 with flatter PK profile | FDA Approved |
| Combination with prandial / mealtime insulins | Adult and pediatric patients with T1DM or insulin-requiring T2DM | Multiple daily injection (MDI) regimen with rapid-acting analogs (lispro, aspart, glulisine) | FDA Approved |
| Combination with GLP-1 receptor agonist (fixed ratio) | Adults with T2DM | Soliqua 100/33 (insulin glargine + lixisenatide) provides combined basal insulin and GLP-1 RA in a single pen | FDA Approved |
| Pediatric use of Toujeo <6 years | — | Safety and efficacy not established | Not Established |
| Diabetic ketoacidosis (DKA) | — | — | Not Recommended |
Insulin glargine is not for the treatment of diabetic ketoacidosis — intravenous short-acting insulin (regular human insulin or rapid-acting analog) is required for DKA management. Within current treatment algorithms, the ADA Standards of Care position basal insulin as preferred when injectable therapy is needed in T2DM, particularly when GLP-1 receptor agonists are insufficient, contraindicated, or the patient has prominent catabolic features (significant weight loss, severe hyperglycemia, ketosis). For T1DM, basal insulin is foundational therapy. Insulin glargine has neutral cardiovascular effects in patients with prediabetes or early T2DM, established by the ORIGIN trial — it neither increases nor reduces cardiovascular events.
Inpatient hyperglycemia management (Evidence: Established off-label) — Basal insulin glargine is widely used in hospitalized non-critical patients as part of basal-bolus protocols, often replacing scheduled NPH or sliding-scale-only regimens. Endorsed by Endocrine Society inpatient guidelines despite labels not specifying inpatient use.
Gestational diabetes / pregnancy (Evidence: Acceptable based on observational data) — Insulin glargine has been used during pregnancy when needed; published studies have not reported a clear association with adverse developmental outcomes per current FDA labeling. NPH and detemir have historically been the most-studied basal insulins in pregnancy; glargine is increasingly accepted with appropriate monitoring.
Cystic fibrosis–related diabetes (CFRD) (Evidence: Acceptable off-label) — Insulin (including basal analogs) is recommended therapy; oral agents are not routinely used.
Steroid-induced hyperglycemia (Evidence: Acceptable, but NPH may be preferred for short-acting steroid coverage) — For chronic glucocorticoid-induced hyperglycemia, basal insulin glargine is reasonable. For prednisone-induced hyperglycemia following morning dosing, intermediate-acting NPH timed to peak 4–8 hours later may align better with the steroid effect.
Dosing
Insulin glargine doses are highly individualized based on metabolic needs, blood glucose monitoring, glycemic control goals, type of diabetes, prior insulin use, and concomitant antihyperglycemic therapy. All formulations are administered by subcutaneous injection only — never intravenously, intramuscularly, or via insulin pump — into the abdomen, thigh, or deltoid, with rotation of injection sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Dosing is once daily at any time of day, but at the same time every day. Insulin glargine must not be diluted or mixed with any other insulin or solution; doing so will alter the precipitation behavior and disrupt the prolonged absorption profile.
Available Pen and Vial Specifications
- Lantus 10 mL multiple-dose vial — 1,000 units total; for use with U-100 syringes.
- Lantus SoloStar prefilled pen — 3 mL (300 units); dials in 1-unit increments.
- Toujeo SoloStar prefilled pen — 1.5 mL (450 units U-300); dials in 1-unit increments; delivers up to 80 units in a single injection.
- Toujeo Max SoloStar prefilled pen — 3 mL (900 units U-300); dials in 2-unit increments; delivers up to 160 units in a single injection; recommended for patients requiring at least 20 units of basal insulin per day.
- Basaglar KwikPen, Semglee pen/vial, Rezvoglar KwikPen — All U-100 (100 units/mL); 3 mL prefilled pens dial in 1-unit increments; 10 mL vial available for Semglee.
| Clinical Scenario | Starting Dose | Titration | Target / Maximum | Notes |
|---|---|---|---|---|
| T1DM — adult or pediatric, insulin-naive | Approximately ⅓ of total daily insulin requirements U-100 or U-300, once daily SC | Adjust by 1–2 U based on FPG; monitor pre-meal and bedtime glucose | Individualized to glycemic targets | Remaining ⅔ of TDD as rapid-acting prandial insulin distributed across meals. |
| T2DM — adult, insulin-naive | 10 units once daily or 0.2 U/kg once daily | Increase 2 U every 3 days based on fasting plasma glucose; target FPG typically 80–130 mg/dL | Individualized; commonly 0.5–1 U/kg/day at full titration | Per FDA Lantus PI starting dose recommendation. Continue oral agents (metformin / SGLT2i / GLP-1 RA) as appropriate. |
| Switching from once-daily NPH insulin to Lantus / U-100 product | Same total daily unit dose | Adjust based on glycemic response over 1–2 weeks | Per FDA Lantus PI. | |
| Switching from twice-daily NPH insulin to Lantus / U-100 product | 80% of the total daily NPH dose, given as once-daily Lantus (= 20% dose reduction) | Adjust over 2–4 weeks | Per FDA Lantus PI Section 2.3 — applies to NPH insulin. | |
| Switching from twice-daily NPH or detemir to Toujeo (U-300) | Start at 80% of total daily NPH or detemir twice-daily dose; once daily | Titrate over 2–4 weeks | Per FDA Toujeo PI. | |
| Switching from Lantus (U-100) to Toujeo (U-300) | Same unit dose initially; expect a higher Toujeo dose may be required at steady state — clinical trial patients used approximately 15% more basal insulin on Toujeo | Titrate based on response | Per FDA Toujeo PI. Toujeo has lower per-unit glucose-lowering effect than Lantus due to slower release from a smaller-surface depot. | |
| Switching from Toujeo (U-300) to Lantus / U-100 product | Initial Lantus dose 80% of the Toujeo dose; once daily | Titrate based on response | Per FDA Lantus PI Section 2.3. Higher per-unit bioavailability with U-100; close glucose monitoring in week 1. | |
| Renal impairment | No specific algorithm in FDA label Use lower starting dose; titrate cautiously | Slow, individualized titration; intensified glucose monitoring | Individualized | Insulin clearance is reduced in renal failure — increased risk of hypoglycemia, particularly at eGFR <30 mL/min. |
| Hepatic impairment | No specific algorithm in FDA label Use lower starting dose; titrate cautiously | Slow titration; intensified glucose monitoring | Individualized | Hepatic gluconeogenesis impairment may prolong hypoglycemia. |
| Older adults (≥65 years) | Conservative initial dose, dose increments, and maintenance dosage | Individualized | Hypoglycemia may be difficult to recognize; prefer less stringent HbA1c targets (e.g., <7.5–8% per ADA). | |
| Soliqua 100/33 (insulin glargine + lixisenatide) | 15 units daily (insulin-naive, on GLP-1 RA, or <30 U basal/day) or 30 units daily (currently on 30–60 U basal/day) | Adjust per glycemic response | 60 units/day max (60 U insulin glargine + 20 mcg lixisenatide) | Discontinue prior basal insulin or GLP-1 RA before initiation. T2DM only. |
| Missed dose | If less than ~12 hours from the missed dose, take as soon as remembered; if closer to the next dose, skip and resume regular schedule | Do not double dose. Monitor SMBG closely on day of missed dose. | ||
Storage Conditions
- Lantus and U-100 biosimilars (unopened): Refrigerated 36–46°F (2–8°C) until expiration date. Do not freeze.
- Lantus 10 mL vial (in-use): 28 days at refrigerator OR room temperature (≤86°F / 30°C). Discard after 28 days regardless of remaining contents.
- Lantus SoloStar pen (in-use): 28 days at room temperature only (≤86°F / 30°C). Do not refrigerate after first use.
- Toujeo SoloStar and Max SoloStar pens (unopened): Refrigerated 36–46°F (2–8°C) until expiration date.
- Toujeo SoloStar / Max SoloStar pens (in-use): 56 days at room temperature only (≤86°F / 30°C). Do not refrigerate after first use.
- All formulations: Protect from direct heat and light. Discard if frozen.
Toujeo U-300 contains three times the insulin concentration of Lantus U-100. Patients must be instructed to never use a syringe to withdraw insulin from a Toujeo SoloStar or Max SoloStar pen — doing so could deliver three times the intended dose, producing severe hypoglycemia. Toujeo SoloStar and Toujeo Max SoloStar pens have a “300 units/mL (U-300)” warning highlighted in honey gold on the label. The dose counter on the pen displays the number of units to be injected, requiring no recalculation. Toujeo SoloStar dials in 1-unit increments; Toujeo Max SoloStar dials in 2-unit increments — when changing between SoloStar and Max SoloStar pens, an odd-number dose should be increased or decreased by 1 unit to match the dose increments dialable on the new pen.
The EDITION trial program (n >3,500 across phase 3 studies in T1DM and T2DM) demonstrated that Toujeo U-300 provides similar HbA1c reduction to Lantus U-100, with a flatter PK profile and reduced nocturnal hypoglycemia in some subpopulations. Toujeo trial patients used approximately 15% more basal insulin units than Lantus patients to achieve equivalent glycemic control, due to slower, more sustained release. Practical advantages of U-300: three times higher concentration permits one-third the injection volume, potentially relevant when daily basal doses exceed 60–80 units; longer in-use stability (56 days vs 28 days). Practical advantages of U-100: wider familiarity, more head-to-head comparator data, and significantly broader access to lower-cost interchangeable biosimilars (Semglee, Rezvoglar).
Pharmacology
Mechanism of Action
Insulin glargine, like all insulins, regulates glucose metabolism by binding the insulin receptor on peripheral tissues — primarily skeletal muscle and adipose tissue — and stimulating glucose uptake while simultaneously inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis and enhances protein synthesis. Insulin glargine has approximately the same receptor-level potency as endogenous human insulin; the molecular modifications affect only its pharmacokinetic profile, not its intrinsic biological activity at the insulin receptor.
The clinical innovation of insulin glargine lies in its delayed and prolonged absorption from the subcutaneous depot. At its formulation pH of approximately 4.0, insulin glargine is fully soluble. Upon subcutaneous injection, neutralization to physiologic pH causes insulin glargine to precipitate as small microcrystals. These microcrystals slowly dissolve and release insulin glargine into the circulation over 24+ hours, producing a relatively peakless basal insulin concentration. With Toujeo U-300, the higher concentration injected as a smaller volume produces a more compact subcutaneous depot with a smaller surface area, which further slows absorption — yielding an even flatter PK profile and a duration of action exceeding 24 hours at typical doses.
In humans, insulin glargine is partly metabolized at the carboxyl terminus of the B-chain in the subcutaneous depot, forming two active metabolites: M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). These metabolites have in vitro insulin receptor binding and biological activity similar to that of human insulin. Both unchanged drug and metabolites are present in the systemic circulation.
Molecular and Formulation Characteristics
- Chemical name: 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin
- Empirical formula: C267H404N72O78S6
- Molecular weight: 6,063 Da
- Formulation pH: ~4 (acidic; precipitates at neutral pH in subcutaneous tissue)
- Lantus inactive ingredients (per mL): 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%
- Toujeo inactive ingredients (per mL): 90 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%
Pharmacokinetic Profile by Formulation
| Parameter | Lantus / U-100 Biosimilars | Toujeo (U-300) |
|---|---|---|
| Onset of action | Approximately 3–4 hours after SC injection | Slightly later than U-100 (~6 hours) |
| Peak concentration | Relatively peakless; modest plateau over 12–18 hours | Tmax 12 (8–14) h at 0.4 U/kg; 12 (12–18) h at 0.6 U/kg; 16 (12–20) h at 0.9 U/kg |
| Duration of action | Up to 24 hours | >24 hours; flatter profile; serum insulin declines beyond 36 hours at higher doses |
| Steady state | Multi-day with once-daily dosing | ≥5 days of once-daily dosing (0.4–0.6 U/kg) |
| Intra-subject variability (CV) | Lower than NPH insulin (specific value not provided in PI) | 21.0% at steady state (24-hour insulin exposure) |
| Injection site effect | No clinically relevant difference among abdomen, thigh, deltoid | No clinically relevant difference among abdomen, thigh, deltoid |
| Glucose-lowering effect per unit (relative) | Reference (100%) | Approximately 27% lower glucose-lowering per unit at 0.4 U/kg vs equivalent Lantus dose |
| Metabolism | Subcutaneous depot cleavage at B-chain C-terminus → active metabolites M1 and M2 (similar in vitro potency to human insulin) | |
| Elimination | Insulin and metabolites cleared by receptor-mediated uptake, hepatic and renal degradation; renal impairment may modestly increase circulating insulin levels | |
HbA1c-Lowering Efficacy
In randomized clinical trials, insulin glargine produces clinically meaningful HbA1c reductions, the magnitude of which depends on baseline HbA1c, prior therapy, and titration intensity. In insulin-naive T2DM patients, basal insulin glargine added to oral antihyperglycemics typically produces meaningful HbA1c reductions over 6 months. In T1DM patients, glargine matches NPH insulin in HbA1c reduction while reducing nocturnal hypoglycemia in many trials. Long-term efficacy was demonstrated in the ORIGIN trial (n=12,537, median follow-up 6.2 years), where insulin glargine maintained near-normal glycemic control and reduced incident new-onset diabetes versus standard care in patients with prediabetes or early T2DM.
Side Effects
Hypoglycemia is the most common and most clinically significant adverse effect of insulin glargine — as with all insulins. The long-acting profile of insulin glargine may delay recovery from hypoglycemic episodes once they occur, requiring sustained carbohydrate intake and observation. Severe hypoglycemia rates in the ORIGIN trial were 1.00 vs 0.31 per 100 patient-years (insulin glargine vs standard care). Modest weight gain (median +1.6 kg vs −0.5 kg in ORIGIN) is typical of insulin therapy generally. Other common adverse effects relate to the injection site (lipodystrophy, localized cutaneous amyloidosis, injection site pain) or are class-wide (peripheral edema, hypokalemia with overdose, immunogenicity). Serious hypersensitivity reactions are rare but can occur.
| Adverse Effect | Rate / Pattern | Clinical Note |
|---|---|---|
| Hypoglycemia (any severity) | Highly dose- and regimen-dependent | The defining adverse effect of insulin therapy; risk increases with intensified glycemic targets, missed meals, exercise, alcohol, and renal/hepatic impairment. |
| Anti-insulin antibodies (Toujeo, T1DM, 6-month study) | 79% positive at least once | Includes 62% positive at baseline and 44% who developed antidrug antibodies during the study. No clinically significant differences in efficacy or safety attributed to antibody formation. |
| Anti-insulin antibodies (Toujeo, T2DM, 6-month studies) | 25% positive at least once | Includes 42% positive at baseline and 20% who developed ADA during the study. Lower rate than in T1DM. No consistent clinical correlate. |
| Weight gain | Median +1.6 kg over 6.2 years (ORIGIN) | Comparable to or slightly less than NPH in head-to-head trials. |
| Adverse Effect | Approximate Incidence | Clinical Note |
|---|---|---|
| Severe hypoglycemia (rate, ORIGIN trial) | 1.00 per 100 patient-years | Versus 0.31 per 100 PY in standard care. Defined as event requiring third-party assistance. |
| Injection site pain (Lantus vs NPH adult trials, FDA PI) | 2.7% (vs 0.7% NPH) | Usually mild and self-limited; rarely leads to discontinuation. Possibly attributable to acidic pH of solution. |
| Lipodystrophy (lipohypertrophy and lipoatrophy) | Site-rotation-dependent; typically 1–5% | Reduced by rotation of injection sites within the same anatomical region. |
| Other injection site reactions (redness, itching, swelling, hives) | ~1–5% | Typically mild and transient. Rotate sites; persistent reactions warrant evaluation. |
| Peripheral edema | Variable | More common with rapid glycemic improvement after long-standing hyperglycemia. Usually transient over weeks. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypoglycemia (coma, seizure, neurologic impairment) | 1.00/100 PY (ORIGIN) | Hours; long-acting profile may delay recovery | IM/SC glucagon or IV concentrated dextrose; sustained carbohydrate intake; observe for recurrence due to long duration of action. |
| Hypokalemia | Particularly with overdose or rapid correction of severe hyperglycemia | Hours | Monitor potassium during initiation, dose changes, and DKA management. Untreated hypokalemia can cause respiratory paralysis, ventricular arrhythmia, and death. |
| Severe hypersensitivity / anaphylaxis | Rare (postmarketing) | Minutes to hours after injection | Discontinue immediately. Severe generalized allergy including anaphylaxis can be life-threatening. Re-challenge only under specialist supervision. |
| Localized cutaneous amyloidosis at injection sites | Postmarketing (incidence not established) | Months to years of repeated injection at same site | Avoid injecting into affected areas. Insulin absorption is impaired in amyloid deposits, leading to unstable glycemia. Rotate injection sites systematically. |
| Heart failure exacerbation (with TZD coadministration) | Class effect of TZD + insulin combinations | Weeks to months | Monitor for signs of heart failure when insulin is combined with rosiglitazone or pioglitazone. Discontinue TZD if heart failure develops or worsens. |
| Medication errors / accidental insulin mix-ups | Reported with all insulin products; particular concern with U-300 | Minutes to hours | Always check insulin labels before administration. Patients must be specifically warned never to use a syringe with Toujeo SoloStar or Max SoloStar pens. |
| Reason for Discontinuation | Pattern | Context |
|---|---|---|
| Recurrent hypoglycemia | Common | Often resolved by dose reduction or switch to a flatter-profile basal insulin (Toujeo, degludec). |
| Cost / formulary changes | Common | Switching to interchangeable biosimilars (Semglee, Rezvoglar) typically clinically equivalent; switch to Basaglar requires new prescription. |
| Adherence / preference | Variable | Some patients with T2DM transition to GLP-1 RA monotherapy or fixed-ratio combination. |
| Lipohypertrophy / amyloidosis | Less common | May require switch to alternative basal insulin or careful site rotation training. |
| Severe hypersensitivity | Rare | Requires permanent discontinuation; alternative basal insulin under specialist supervision. |
Severe hypoglycemia from insulin glargine is a medical emergency. Mild episodes (intact consciousness, able to swallow): treat with 15 g of fast-acting oral carbohydrate, recheck in 15 minutes, and provide a follow-up snack containing complex carbohydrates and protein. Severe episodes (coma, seizure, inability to swallow): administer subcutaneous, intramuscular, or intranasal glucagon if available, or call emergency services for IV concentrated dextrose. Critical: because the duration of action of insulin glargine is up to 24 hours (and longer with U-300), recurrence is common after apparent recovery. Sustained carbohydrate intake and observation for at least several hours, often longer, are required. Hypokalemia must be corrected appropriately.
Drug Interactions
Insulin glargine is a peptide and does not undergo CYP-mediated metabolism — it has no relevant CYP enzyme inhibition or induction potential. The clinically significant interactions are pharmacodynamic, falling into three categories per FDA Lantus PI Table 8: (1) drugs that increase the blood-glucose-lowering effect of insulin, raising hypoglycemia risk; (2) drugs that decrease the blood-glucose-lowering effect, raising hyperglycemia risk; and (3) drugs that may both increase or decrease glycemic control depending on dose, duration, and individual factors. A separate small but important category is drugs that blunt the symptoms of hypoglycemia, which do not change insulin’s effect but mask the patient’s ability to recognize hypoglycemia.
Monitoring
Monitoring of insulin glargine therapy centers on glycemic response, hypoglycemia surveillance, injection site assessment, and management of intercurrent factors that affect insulin requirements (renal/hepatic function, intercurrent medications, illness, lifestyle). Self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) is foundational — particularly during initiation, titration, intercurrent illness, and changes in concomitant medications. CGM is increasingly recommended for all patients with T1DM and for many T2DM patients on multiple-daily-injection regimens.
-
HbA1c
Every 3 months until at goal, then every 6 months
Routine Target individualized — generally <7% for most adults; <6.5% if achievable safely without hypoglycemia; <7.5–8% for older adults, those with comorbidities, or those with a history of severe hypoglycemia. -
Fasting Plasma Glucose (FPG)
Daily during titration; periodically thereafter
Routine Primary parameter for titrating basal insulin glargine. Common targets: 80–130 mg/dL (4.4–7.2 mmol/L) per ADA, with individualization for older adults and those at hypoglycemia risk. -
Self-Monitored Blood Glucose / CGM
Multiple times daily for T1DM and intensive T2DM regimens
Routine CGM preferred where available. Time-in-range (TIR; 70–180 mg/dL) goal >70%. Critical during initiation, dose escalation, illness, and concomitant medication changes. -
Hypoglycemia Symptoms
Every visit; immediate review with new symptoms
Trigger-based Specifically inquire about unexplained dizziness, sweating, tremor, palpitations, confusion — particularly nocturnal episodes. Beta-blocker users may lose adrenergic warning signs. Consider Gold or Clarke score for hypoglycemia awareness assessment. -
Injection Sites
At least annually; with any unexplained glycemic instability
Trigger-based Inspect and palpate for lipohypertrophy, lipoatrophy, and localized cutaneous amyloidosis. Insulin absorption from such areas is impaired and erratic, often manifesting as unexplained glycemic instability. -
Body Weight
Each visit
Routine Modest weight gain is typical. Significant gain may prompt review of caloric intake, addition of GLP-1 RA or SGLT2 inhibitor, or dose optimization. -
Renal Function (eGFR)
At baseline; annually thereafter (more often in CKD)
Routine Worsening renal function reduces insulin clearance — increased hypoglycemia risk. Dose reduction often needed at eGFR <30 mL/min. -
Liver Function
At baseline; periodically
Trigger-based Hepatic gluconeogenesis impairment increases hypoglycemia risk. Glycemic instability in advanced liver disease often requires reduced insulin doses and intensified monitoring. -
Serum Potassium
During DKA management or insulin overdose
Trigger-based Insulin drives potassium intracellularly. Hypokalemia is a particular concern in DKA, with rapid correction of severe hyperglycemia, and in renal failure. -
Lipid Panel & BP
Per general CV risk management guidelines
Routine Insulin glargine has neutral effects on lipoprotein profile. Standard CV risk surveillance applies. -
Annual Diabetes Care Bundle
Annually
Routine Diabetic retinopathy screening, urine albumin/creatinine, foot examination, dental review, immunizations. Per ADA Standards of Care.
Contraindications & Cautions
Toujeo U-300 contains three times the insulin concentration of Lantus U-100. To prevent severe hypoglycemia from inadvertent overdose, instruct patients to use only the integrated dose counter on the Toujeo SoloStar or Toujeo Max SoloStar pen — never withdraw insulin from a Toujeo pen using a syringe. Drawing 30 units from a U-300 pen using a U-100 syringe would deliver 90 units of insulin glargine. Pen labels are color-coded with “300 units/mL (U-300)” highlighted in honey gold. Toujeo SoloStar dials in 1-unit increments (max 80 units single injection); Toujeo Max SoloStar dials in 2-unit increments (max 160 units single injection).
Absolute Contraindications
- Known hypersensitivity to insulin glargine or any excipient. Severe allergic reactions, including anaphylaxis, have occurred.
- During an episode of hypoglycemia — do not administer insulin in a hypoglycemic patient.
Relative Contraindications / Use with Caution
- Diabetic ketoacidosis (DKA) — insulin glargine is not appropriate primary treatment; intravenous regular insulin is required.
- Hyperosmolar hyperglycemic state (HHS) — IV insulin is preferred initially; basal insulin glargine can be added during the transition phase to subcutaneous therapy.
- Severe renal impairment — insulin clearance is reduced; lower starting doses and slower titration are required to prevent severe and prolonged hypoglycemia.
- Severe hepatic impairment — diminished gluconeogenic capacity raises hypoglycemia risk. Conservative dosing and intensified monitoring required.
- Concomitant thiazolidinedione (TZD) therapy — risk of fluid retention, edema, and heart failure exacerbation, particularly in patients with NYHA class III–IV heart failure.
- Older adults — heightened hypoglycemia risk; conservative dosing; relaxed glycemic targets generally appropriate (HbA1c <7.5–8%).
- Acute illness, surgery, or interrupted oral intake — insulin requirements change abruptly; doses should be adjusted with intensified monitoring or IV insulin substitution where appropriate.
- Pregnancy — insulin glargine has been used during pregnancy; published studies have not reported a clear association with adverse developmental outcomes, though insulin detemir and NPH have historically had more pregnancy-specific data. Maternal hyperglycemia management benefits the fetus.
- Lactation — compatible. Endogenous insulin is present in human milk and is not absorbed orally by the infant. Maternal insulin requirements may decrease postpartum during breastfeeding.
- Visual impairment — patients who cannot read pen markings should not self-administer without assistance. Pens have audible clicks but should not be relied upon as the sole dose verification.
- Driving and operating heavy machinery — hypoglycemia impairs concentration and reaction time. Stable glycemic control should be ensured before resuming such activities, particularly during titration.
Patient Counselling
Purpose of Therapy
Explain that insulin glargine is a long-acting “background” or “basal” insulin that works for about a full day after each injection, providing the constant low level of insulin your body needs between meals and overnight. It does not replace insulin taken with meals. The two main concerns are low blood sugar (hypoglycemia) and weight gain. Most people on insulin glargine also use a fast-acting insulin at meals (for type 1 diabetes) or oral diabetes medications like metformin, GLP-1 agonists, or SGLT2 inhibitors (for type 2 diabetes).
How to Inject
Inject once daily at the same time every day, into the subcutaneous tissue of the abdomen (avoiding the area within 2 inches of the navel), the front or outer thigh, or the back of the upper arm. Rotate injection sites within the same anatomical region to prevent lumpy or hardened areas (lipohypertrophy) that can affect insulin absorption. The insulin solution should be clear and colorless — do not use if cloudy, discolored, or contains particles.
Lantus U-100, Basaglar, Semglee, Rezvoglar: These are 100 units per mL. Standard insulin syringes (U-100) or the SoloStar/KwikPen prefilled pens can be used.
Toujeo U-300: This is three times more concentrated — 300 units per mL. Never use a syringe to withdraw insulin from a Toujeo pen. Use only the dose counter on the Toujeo SoloStar (dials in 1-unit increments, max 80 units per injection) or Toujeo Max SoloStar pen (dials in 2-unit increments, max 160 units per injection). The honey-gold “300 units/mL” label on the pen confirms the concentration.
Storage — Lantus and U-100 biosimilars: Unused pens and vials should be kept in the refrigerator (36–46°F / 2–8°C) until first use. Do not freeze. Once in use, Lantus pens are kept at room temperature (below 86°F / 30°C) and discarded after 28 days. Lantus vials in use can be kept refrigerated or at room temperature and discarded after 28 days. Storage — Toujeo: Unused pens refrigerated until first use; once in use, kept at room temperature only and discarded after 56 days. Never share insulin pens or syringes with another person, even with a new needle, due to bloodborne disease transmission risk.
Sources
- U.S. Food and Drug Administration. Lantus (insulin glargine) injection, for subcutaneous use. Sanofi-Aventis. Initial U.S. Approval: 2000 (NDA 21081). accessdata.fda.gov Definitive U.S. labeling for Lantus U-100 — primary source for indications, dosing (T1DM ⅓ TDD; T2DM 10 U or 0.2 U/kg starting dose; twice-daily NPH→Lantus 80% conversion; Toujeo→Lantus 80% conversion), pharmacokinetics (M1/M2 active metabolites; relatively peakless 24-hour profile), drug interactions (Table 8), Study D pediatric population (ages 6–15, T1DM, n=174 LANTUS-treated), and adverse reactions.
- U.S. Food and Drug Administration. Toujeo U-300 (insulin glargine) injection, for subcutaneous use. Sanofi-Aventis. Initial U.S. Approval: 2015 (NDA 206538). accessdata.fda.gov Definitive U.S. labeling for Toujeo U-300 — primary source for U-300-specific PK (Tmax 12–16 h dose-dependent, ≥5 days to steady state, 21% intra-subject variability, ~27% lower glucose-lowering per unit at 0.4 U/kg vs Lantus), conversion ratios from NPH or detemir (80%) and Lantus (same dose initially; ~15% more units typical), pediatric ≥6 yr indication, anti-insulin antibody data (T1DM 79%, T2DM 25% positive at least once), and pen specifications (SoloStar 1-U increments / 80 U max single inject; Max SoloStar 2-U increments / 160 U max single inject).
- U.S. Food and Drug Administration. Soliqua 100/33 (insulin glargine and lixisenatide) injection prescribing information. Sanofi-Aventis. lantus.com Reference for fixed-ratio insulin glargine + lixisenatide combination dosing (15-unit start for insulin-naive / GLP-1 RA users / <30 U basal/day; 30-unit start for 30–60 U basal/day; 60-unit/day maximum corresponding to 20 mcg lixisenatide ceiling).
- National Library of Medicine, DailyMed. Lantus and Toujeo full prescribing information. dailymed.nlm.nih.gov Continuously updated full prescribing information for cross-checking the most current label changes for both Lantus and Toujeo.
- ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328. doi.org/10.1056/NEJMoa1203858 · PMID 22686416 The definitive cardiovascular outcomes trial of insulin glargine: n=12,537 patients with prediabetes or early T2DM, mean age 63.5 years, median 6.2-yr follow-up. First coprimary outcome (CV death/MI/stroke) HR 1.02 (95% CI 0.94–1.11; P=0.63); second coprimary outcome (with revasc/HHF) HR 1.04 (0.97–1.11; P=0.27). Severe hypoglycemia 1.00 vs 0.31/100 PY; weight +1.6 vs −0.5 kg; new diabetes 30% vs 35% (OR 0.80; 95% CI 0.64–1.00; P=0.05); no cancer signal (HR 1.00; 0.88–1.13). Established the cardiovascular safety of insulin glargine.
- ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, et al. Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Circulation. 2016;133(9):891–894 (presented at ADA; full data in Diabetes Care). PMID 26681720 Post-trial follow-up (additional 2.7 years) of ORIGIN — confirmed neutral cardiovascular outcomes (HR 1.01; 95% CI 0.94–1.10) and absence of cancer signal (HR 0.99; 0.88–1.12) with insulin glargine after a total of >9 years of observation.
- Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762. doi.org/10.2337/dc14-0991 · PMID 25078900 EDITION 1: T2DM on basal+mealtime insulin (n=807, 6 months). HbA1c reduction equivalent (LSM difference 0.00%; 95% CI −0.11 to 0.11). Nocturnal hypoglycemia lower with Gla-300 (36% vs 46%; RR 0.79; 95% CI 0.67–0.93; P<0.005). Established U-300 efficacy with reduced nocturnal hypoglycemia.
- Yki-Järvinen H, Bergenstal R, Ziemen M, et al; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–3243. doi.org/10.2337/dc14-0990 EDITION 2: T2DM on basal insulin + oral antihyperglycemic drugs. Confirmed glycemic equivalence and reduced nocturnal hypoglycemia of Gla-300 vs Gla-100 in this population.
- Bolli GB, Riddle MC, Bergenstal RM, et al; EDITION 3 Study Investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394. doi.org/10.1111/dom.12438 EDITION 3: Insulin-naive T2DM patients on oral glucose-lowering drugs. Demonstrated comparable HbA1c reduction with Gla-300 vs Gla-100 in this initiation population.
- Home PD, Bergenstal RM, Bolli GB, et al; EDITION 4 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–2225. doi.org/10.2337/dc15-0249 EDITION 4: T1DM on basal-bolus regimen (n=549). HbA1c reduction equivalent between Gla-300 and Gla-100. Nocturnal hypoglycemia lower with Gla-300 in the first 8 weeks (RR 0.69; 95% CI 0.53–0.91); thereafter equivalent.
- U.S. Food and Drug Administration. FDA approves first interchangeable biosimilar insulin product (Semglee; insulin glargine-yfgn). July 28, 2021. fda.gov Semglee (insulin glargine-yfgn; Viatris/Biocon) — the first interchangeable biosimilar to Lantus.
- U.S. Food and Drug Administration. Approval of Rezvoglar (insulin glargine-aglr) as biosimilar (December 17, 2021) and as interchangeable (November 16, 2022). Rezvoglar (insulin glargine-aglr; Eli Lilly) — second interchangeable biosimilar of Lantus. Basaglar (insulin glargine; Eli Lilly), an earlier follow-on insulin glargine product approved December 2015, is a biosimilar but not designated interchangeable, so substitution at the pharmacy level requires a new prescription.
- American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes. Diabetes Care. Updated annually. diabetesjournals.org/care Authoritative U.S. guidance on insulin initiation and titration in T1DM and T2DM, including basal-bolus and basal-plus-GLP-1 RA approaches.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi.org/10.2337/dci22-0034 ADA-EASD consensus on the role of basal insulin in T2DM management, including conditions where basal insulin remains preferred (catabolic features, severe hyperglycemia, intolerance/contraindication to other agents).
- American Diabetes Association. Glycemic Targets: Standards of Care in Diabetes. Diabetes Care. Updated annually. Current targets for HbA1c, FPG, postprandial glucose, and CGM time-in-range.
- Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units · mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL−1. Diabetes Care. 2015;38(4):637–643. doi.org/10.2337/dc14-0006 Pharmacodynamic and pharmacokinetic comparison of Toujeo U-300 versus Lantus U-100 — demonstrated flatter activity profile and longer duration of U-300 in euglycemic clamp studies.
- Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–451. Foundational head-to-head study of insulin glargine vs NPH in metformin-treated T2DM; established the favorable nocturnal hypoglycemia profile of glargine.